FDA approves 2mg Narcan nasal spray for opioid overdose treatment

Adapt Pharma said today that the FDA approved the 2mg formulation of its Narcan nasal spray for the emergency treatment of opioid overdose.

The 2mg dose is intended for opioid-dependent patients that are at risk for severe withdrawal, but are not at a high risk for continued opioid exposure. The approval comes 1 year after the FDA approved its 4mg formulation, which was the 1st needle-free version of naloxone.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves 2mg Narcan nasal spray for opioid overdose treatment appeared first on MassDevice.

from MassDevice http://ift.tt/2jROczC